{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-L28Z18ZD/2e24c4dc-1af6-43a6-b9f6-f8d38eaa9c92/HTML","dcterms:extent":"40 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-L28Z18ZD/91576fee-94f1-43f5-b6f0-9a10630ff1a9/PDF","dcterms:extent":"188 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-L28Z18ZD/4c409d0a-afd4-4c57-a7ab-f21e9d0be5ce/TEXT","dcterms:extent":"24 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-L28Z18ZD","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"2003","dc:creator":["Cör, Andrej","Pižem, Jože"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:37"},{"@xml:lang":"sl","#text":"8 strani"},{"@xml:lang":"sl","#text":"str. 195-202"}],"dc:identifier":["ISSN:1318-2099","COBISSID:17000409","URN:URN:NBN:SI:doc-L28Z18ZD"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Association of Radiology and Oncology"},"dc:subject":[{"@xml:lang":"en","#text":"Apoptosis"},{"@xml:lang":"sl","#text":"Apoptoza"},{"@xml:lang":"sl","#text":"Beljakovina p53"},{"@xml:lang":"en","#text":"Cysteine Proteinases"},{"@xml:lang":"en","#text":"Diagnostic Use"},{"@xml:lang":"en","#text":"Drug Effects"},{"@xml:lang":"en","#text":"Drug Therapy"},{"@xml:lang":"en","#text":"molecular biology"},{"@xml:lang":"sl","#text":"molekularna biologija"},{"@xml:lang":"en","#text":"Neoplasms"},{"@xml:lang":"sl","#text":"Novotvorbe"},{"@xml:lang":"sl","#text":"onkologija"},{"@xml:lang":"en","#text":"Protein P53"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"en","#text":"Therapeutic Use"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"en","#text":"tumor"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Survivin - an inhibitor of apoptosis and a new therapeutic target in cancer|"},"dc:description":[{"@xml:lang":"sl","#text":"Survivin is a unique member of the inhibitor of apoptosis (IAP) protein family. It inhibits apoptosis by interfering with post-mitochondrial events during apoptosis, thus blocking activation of caspases. The expression of survivin is among the most tumour specific of all human genes. It is overexpressed in most human cancers but is not detected in most normal tissues. Some molecular mechanisms of survivin upregulation in cancer have been elucidated, including loss of the wild-type p53. Tumours that overexpresssurvivin generally bear a worse prognosis and are associated with resistance to therapy. Its differential expression in caneer versus normal tissues makes survivin detection a useful tool in cancer diagnostics and a promising therapeutic target. Survivin targeting has resulted in increased spontaneous and induced apoptosis and inhibition of tumourgrowth. Some anticaneer drugs currently introduced into clinical practice might well act byinactivaring survivin"},{"@xml:lang":"sl","#text":"Survivin sodi v družino beljakovin zaviralcev apoptoze (inhibitor of apoptosis, IAP). Zavira aktivacijo kaspaz, tako da vpliva na \"po-mitohondrijske\" dogodke med apoptozo. Survivin se (prekomerno) izraža v večini tumorjev, v normalnih tkivih pa ne. Poznani so nekateri molekularni mehanizmi, ki so odgovorni za prekomerno izražanje survivina v tumorjih, eden takih je izguba divjega tipa beljakovine p53. Tumorji, ki izražajo survivin, so v splošnem manj občutljivi na zdravljenje, preživetje bolnikov je slabše. Zaradi različnega izražanja survivina v tumorskem in netumorskem tkivu je survivin uporaben v molekularni diagnostiki tumorjev, hkrati pa primerna tarčaza razvoj takšnega načina zdravljenja, ki je usmerjeno proti tumorju in čim manj poškoduje normalna tkiva. Zaviranje delovanja survivina vodi v povečano spontano ali sproženo celično smrt (apoptozo), kar zavre rast tumorja. Nekatera novejša zdravila proti raku verjetno delujejo v veliki meri preko zaviranja delovanja survivina"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-L28Z18ZD","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-L28Z18ZD"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-L28Z18ZD/91576fee-94f1-43f5-b6f0-9a10630ff1a9/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo radiologije in onkologije"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-L28Z18ZD/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-L28Z18ZD"}}}}